Pemgarda (pemivibart) is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Clinicians are authorized to administer the drug, which must be infused for at least an hour and be followed by a repeat dose every three months. It is authorized for use in patients who are immunocompromised because of a medical condition, or those who are taking immunosuppressive medications and are unlikely to be protected with a COVID-19 vaccine.
In an ongoing phase 3 trial, the “calculated serum neutralizing antibody titers against JN.1” matched efficacy data for other monoclonal antibody products, the Massachusetts-based manufacturer, Invivyd, said in a news release.
Side effects include hypersensitivity, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache and nausea; and its warning label lists anaphylaxis and cross-hypersensitivity with COVID-19 vaccines.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
